Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. OpGen, Inc.
  6. News
  7. Summary
    OPGN   US68373L3078

OPGEN, INC.

(OPGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Opgen, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

08/12/2021 | 05:05pm EDT

OpGen, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 811,615 compared to USD 1.188 million a year ago. Operating loss was USD 6.138 million compared to USD 6.517 million a year ago. Net loss was USD 7.086 million compared to USD 7.475 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.49 a year ago. For the half year, total revenue was USD 1.641 million compared to USD 1.805 million a year ago. Operating loss was USD 12.399 million compared to USD 10.512 million a year ago. Net loss was USD 21.937 million compared to USD 11.424 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 1 a year ago.


ę S&P Capital IQ 2021
All news about OPGEN, INC.
10/15OPGEN : Announces $15 Million Registered Direct Offering - Form 8-K
PU
10/15OPGEN INC : Entry into a Material Definitive Agreement, Material Modification to Rights of..
AQ
10/14OPGEN : Launches $15 Million Registered Direct Offering
MT
10/14OPGEN : Announces $15 Million Registered Direct Offering
AQ
10/08OPGEN : Corporate Presentation (PDF)
PU
10/04Wall Street Set for Losses, Supply Chain Woes Dent Sentiment
MT
10/04Health Care Stocks Trade Lower Pre-Bell Monday
MT
10/04OPGEN : Health Care
MT
10/04OPGEN : Receives FDA Clearance for Launch of Acuitas AMR Gene Panel; Provides Preliminary ..
MT
10/04OPGEN : Corporate Presentation (PDF)
PU
More news
Analyst Recommendations on OPGEN, INC.
More recommendations
Financials (USD)
Sales 2021 3,90 M - -
Net income 2021 -38,4 M - -
Net Debt 2021 7,16 M - -
P/E ratio 2021 -1,92x
Yield 2021 -
Capitalization 77,7 M 77,7 M -
EV / Sales 2021 21,8x
EV / Sales 2022 8,26x
Nbr of Employees 102
Free-Float 99,8%
Chart OPGEN, INC.
Duration : Period :
OpGen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPGEN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,03 $
Average target price 5,00 $
Spread / Average Target 146%
EPS Revisions
Managers and Directors
Oliver Schacht Chief Executive Officer & Director
William E. Rhodes Non-Executive Chairman
Vadim Sapiro Chief Information Officer
Faranak Atrzadeh Chief Marketing & Scientific Affairs Officer
Johannes Bacher Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
OPGEN, INC.-0.49%78
MODERNA, INC.210.34%130 866
LONZA GROUP AG26.90%58 060
IQVIA HOLDINGS INC.38.89%47 683
SEAGEN INC.-1.38%31 426
CELLTRION, INC.-38.72%25 414